Oregon Public Employees Retirement Fund Has $46.75 Million Position in AbbVie Inc. $ABBV

Oregon Public Employees Retirement Fund lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 32.2% during the 3rd quarter, Holdings Channel reports. The firm owned 201,906 shares of the company’s stock after purchasing an additional 49,170 shares during the quarter. AbbVie comprises 0.6% of Oregon Public Employees Retirement Fund’s portfolio, making the stock its 23rd biggest holding. Oregon Public Employees Retirement Fund’s holdings in AbbVie were worth $46,749,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. Campbell Newman Asset Management Inc. lifted its stake in AbbVie by 2.0% during the third quarter. Campbell Newman Asset Management Inc. now owns 161,861 shares of the company’s stock worth $37,477,000 after purchasing an additional 3,188 shares during the last quarter. Capital Investment Advisors LLC lifted its holdings in shares of AbbVie by 59.5% in the third quarter. Capital Investment Advisors LLC now owns 305,950 shares of the company’s stock worth $70,840,000 after acquiring an additional 114,177 shares during the last quarter. Family Capital Trust Co acquired a new stake in shares of AbbVie in the 3rd quarter valued at approximately $1,966,000. Joseph Group Capital Management bought a new position in AbbVie in the 3rd quarter valued at approximately $201,000. Finally, Essex LLC lifted its stake in shares of AbbVie by 14.8% in the 3rd quarter. Essex LLC now owns 4,567 shares of the company’s stock valued at $1,057,000 after acquiring an additional 588 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Pipeline progress: AbbVie advanced its Phase 2 icalcaprant trial in depression, which keeps a potential late-stage CNS asset on the radar and preserves upside if clinical data are positive. Read More.
• Positive Sentiment: New oncology program: AbbVie launched a first‑in‑human ABBV‑901 ovarian cancer trial, expanding its oncology pipeline and creating a longer-term growth optionality. Read More.
• Positive Sentiment: Real‑world evidence readouts: Post‑marketing/observational studies for Rinvoq (Korea) and upadacitinib (Japan) wrapped up, which can support label, payer conversations and uptake in key markets. Read More. Read More.
• Positive Sentiment: Analyst support and dividend narrative: Berenberg upgraded to a Buy and investor commentary emphasizing AbbVie’s reliable dividend/ income profile may underpin longer‑term demand from income-focused funds. Read More. Read More.
• Neutral Sentiment: Event calendar: AbbVie scheduled its full‑year and Q4 2025 earnings release and call for Feb. 4 — an upcoming catalyst where management can clarify guidance drivers. Read More.
• Negative Sentiment: Guidance nudged below consensus: AbbVie updated Q4 2025 EPS to $3.320–3.360 (vs. street ~3.360) and FY 2025 to $10.610–10.650 (vs. ~10.650), a small miss that removes near‑term upside expectations. (Company guidance release)
• Negative Sentiment: One‑time accounting hit: Management flagged IPR&D and related expenses that will negatively impact Q4 EPS, pressuring reported profitability this quarter. Read More.
• Negative Sentiment: M&A rumor volatility: Reports the company was in talks to buy Revolution Medicines briefly lifted both stocks; AbbVie subsequently denied talks, a reversal that likely contributed to intraday selling pressure. Read More. Read More.

AbbVie Price Performance

NYSE ABBV opened at $224.22 on Friday. The business’s fifty day moving average is $226.55 and its 200-day moving average is $214.86. The stock has a market capitalization of $396.28 billion, a price-to-earnings ratio of 169.86, a PEG ratio of 0.98 and a beta of 0.36. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same quarter in the previous year, the firm posted $3.00 earnings per share. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. AbbVie’s dividend payout ratio is 496.97%.

Analyst Ratings Changes

Several research firms recently commented on ABBV. Guggenheim lifted their target price on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Piper Sandler reaffirmed an “overweight” rating and set a $289.00 target price (up from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Bank of America raised their price target on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Erste Group Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Finally, HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and increased their price objective for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $246.89.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.